Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Lymph Node Pathologic Grading Strategy

Recruiting

Conditions: Lung Adenocarcinoma

First Posted Date: 2024-12-20

Last Posted Date: 2024-12-20

Lead Sponsor: Fudan University

Target Recruit Count: 2998

Registration Number: NCT06745830

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

POLA-R-CHP in the First-line Treatment of Transformed DLBCL

Phase 2

Recruiting

Conditions: Transformed Lymphoma

Interventions: Drug: POLA-R-CHP

First Posted Date: 2024-12-20

Last Posted Date: 2024-12-20

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06743945

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

Phase 2

Not yet recruiting

Conditions: Prostate Cancer Metastatic Disease

Interventions: Drug: HRS-2189
Drug: HRS-5041

First Posted Date: 2024-12-18

Last Posted Date: 2024-12-18

Lead Sponsor: Fudan University

Target Recruit Count: 90

Registration Number: NCT06738745

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

A Phase II, Single-arm, Single-centre Trial to Evaluate the Efficacy and Safety of Nalusobasumab in Combination with Stereotactic Radiosurgery to Improve the Efficacy of First-line Chemotherapy Combined with Immunotherapy in Patients with Bone Metastases from Advanced Non-small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: NSCLC
Stereotactic Body Radiation Therapy (SBRT)
Immunotherapy

Interventions: Drug: nalusobasumab

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: Fudan University

Target Recruit Count: 27

Registration Number: NCT06738160

Reverse Luminal Immune Resistant Breast Cancer

Phase 2

Recruiting

Conditions: Luminal Breast Cancer

Interventions: Drug: Retinoic Acid
Drug: anti-PD-1 antibody and chemotherapy

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Fudan University

Target Recruit Count: 10

Registration Number: NCT06731140

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2

Not yet recruiting

Conditions: Triple Negative Breast Cancer (TNBC)
Metastatic Breast Cancer

Interventions: Drug: Ivarmacitinib
Drug: Camrelizumab (SHR-1210)
Drug: Eribulin

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT06731153

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma

Phase 2

Recruiting

Conditions: Stomach Adenocarcinoma
Gastro-esophageal Junction Cancer

Interventions: Radiation: HFRT targeted to the primary lesion and positive lymph nodes
Radiation: PULSAR targeted to the primary lesion and positive lymph nodes
Drug: Anti-PD-1 monoclonal antibody
Drug: Chemotherapy
Procedure: R0 total/subtotal gastrectomy with D2 lymphadenectomy

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT06728657

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

Early Phase 1

Not yet recruiting

Conditions: Advanced Malignant Solid Tumor

Interventions: Biological: IDOV-SAFE

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Fudan University

Target Recruit Count: 38

Registration Number: NCT06718946

Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis

Phase 1

Not yet recruiting

Conditions: Breast Cancer Metastatic
Breast Cancer Brain Metastases

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Fudan University

Target Recruit Count: 74

Registration Number: NCT06718933

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer

Recruiting

Conditions: Breast Cancer
Age

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-20

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT06718010

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy